|1.||Atadja, Peter: 21 articles (02/2014 - 08/2003)|
|2.||McKinsey, Timothy A: 20 articles (03/2015 - 08/2002)|
|3.||Olson, Eric N: 18 articles (03/2014 - 08/2002)|
|4.||Grant, Steven: 16 articles (06/2013 - 07/2003)|
|5.||Dashwood, Roderick H: 16 articles (09/2012 - 02/2006)|
|6.||Chen, Ching-Shih: 13 articles (01/2015 - 08/2005)|
|7.||Alam, Hasan B: 12 articles (01/2016 - 03/2006)|
|8.||Ho, Emily: 12 articles (12/2015 - 03/2006)|
|9.||Kim, Hyung Sik: 11 articles (09/2015 - 09/2007)|
|10.||Barnes, Peter J: 11 articles (03/2013 - 01/2004)|
01/15/2009 - "Global inhibition of class I and II histone deacetylases (HDACs) stops cancer cell proliferation in vitro and has proven effective against cancer in clinical trials, at least in part, through transcriptional reactivation of the p21(WAF1/Cip1)gene. "
06/01/2014 - "Drugs with histone deacetylase activity are in clinical trials for cancer and certain inflammatory diseases with high safety profiles and they hold similar promise for amelioration of type 1 diabetes with diminished secondary complications. "
10/01/2008 - "In this mini-review, we provide an overview of the histone deacetylase superfamily, highlight the positive results of deacetylase inhibitors in cancer clinical trials, and comment on the prospects for the next generation of such inhibitors."
01/01/2015 - "Previous studies have shown that histone deacetylase 6 (HDAC6) plays critical roles in many cellular processes related to cancer. "
01/01/2015 - "In this study, a number of analogues of DzNep were examined for DzNep-like ability to induce synergistic apoptosis in cancer cells in combination with trichostatin A, a known histone deacetylase (HDAC) inhibitor. "
|2.||Neurodegenerative Diseases (Neurodegenerative Disease)
01/01/2013 - "Targeting histone deacetylase (HDAC) in neuronal survival and neuroprotection may be beneficial in the treatment and prevention of neurodegenerative disorders. "
02/02/2011 - "Although it is well established that pharmacological inhibitors of classical histone deacetylases (HDACs) are protective in various in vivo models of neurodegenerative disease, the identity of the neurotoxic HDAC(s) that these inhibitors target to exert their protective effects has not been resolved. "
01/01/2016 - "Histone deacetylase 6 (HDAC6) controls several major cellular responses to stress that play a role in neurodegenerative diseases, including aggresome formation, autophagy, and apoptosis. "
12/19/2014 - "SIRT1, a class III histone deacetylase, protects neurons in various models of neurodegenerative diseases. "
01/01/2014 - "We have then focused on class III histone deacetylases SIRT1 and SIRT2 that are considered relevant in neurodegenerative diseases. "
|3.||Breast Neoplasms (Breast Cancer)
02/01/2012 - "Our study suggests that LSD1 intimately interacts with histone deacetylases in human breast cancer cells. "
01/01/2009 - "In this study, we investigated the effect of a demethylating agent, a histone deacetylase(HDAC) inhibitor, and the two agents combined on radiosensitivity in human colon and breast cancer cell lines. "
01/01/2016 - "Inhibitor of histone deacetylases (HDACIs) have great therapeutic value for triple negative breast cancer (TNBC) patients. "
03/31/2015 - "Mutating these residues abrogates interaction of MBD2 with the histone deacetylase core and impairs the ability of MBD2 to repress the methylated tumor suppressor gene PRSS8 in MDA-MB-435 breast cancer cells. "
07/01/2012 - "Here we reported a novel potential anticancer strategy by using histone deacetylase (HDAC) inhibitor to enhance the action of endocrine therapy in ERα-positive breast cancer cell. "
|4.||Huntington Disease (Huntington's Disease)
08/08/2013 - "Histone Deacetylase 4 (HDAC4) Inhibitors: A Promising Treatment for Huntington's Disease."
12/15/2012 - "We previously demonstrated that the histone deacetylase (HDAC) inhibitor, 4b, which preferentially targets HDAC1 and HDAC3, ameliorates Huntington's disease (HD)-related phenotypes in different HD model systems. "
01/01/2013 - "This report represents a detailed description of experiments designed to replicate and extend the findings of a published study on the effects of treating the R6/2 Huntington's disease (HD) mouse model with ~300 CAG repeats using the pimelic diphenylamide histone deacetylase (HDAC) inhibitor, HDACi 4b (Thomas et al., 2008). "
10/01/2015 - "Transcriptional dysregulation in Huntington's disease: The role of histone deacetylases."
09/01/2015 - "Genetic deletion of the Histone Deacetylase 6 exacerbates selected behavioral deficits in the R6/1 mouse model for Huntington's disease."
|5.||Colonic Neoplasms (Colon Cancer)
02/01/2015 - "Together, these findings indicate that aceroside VIII is a specific histone deacetylase 6 inhibitor and points to a mechanism by which natural histone deacetylase 6-selective inhibitors may enhance the efficacy of other histone deacetylase 6 inhibitors in colon cancer cells. "
08/07/2015 - "In the current study, we investigated the potential activity of AR-42, a novel histone deacetylase (HDAC) inhibitor, against colon cancer cells. "
03/01/2006 - "We recently reported that SFN acts as a histone deacetylase (HDAC) inhibitor in human colon cancer cells in vitro, and the present study sought to extend these findings in vivo. "
09/01/2014 - "The interplay between histone deacetylases and c-Myc in the transcriptional suppression of HPP1 in colon cancer."
02/01/2007 - "We recently reported on a novel mechanism of chemoprotection by SFN in human colon cancer cells and prostate epithelial cells, namely the inhibition of histone deacetylase (HDAC). "
|1.||Histone Deacetylase Inhibitors
|2.||DNA (Deoxyribonucleic Acid)
|3.||vorinostat (suberoylanilide hydroxamic acid)
|4.||Valproic Acid (Valproate, Semisodium)
|6.||trichostatin A (A 300)
|7.||Proteasome Endopeptidase Complex (Proteasome)
|8.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|1.||Drug Therapy (Chemotherapy)
|4.||Heterologous Transplantation (Xenotransplantation)